GlycoNex secures Japan’s PMDA approval for GNX1021 Phase I trial

​GlycoNex has received Japan’s PMDA approval to commence a first-in-human Phase I clinical trial of GNX1021, its lead ADC candidate, for advanced gastrointestinal cancers.

The post GlycoNex secures Japan’s PMDA approval for GNX1021 Phase I trial appeared first on Hospital Management.

 

Back to the Featured Stories

Featured Stories

AIP to acquire Avanos Medical for $1.27bn
Lilly to acquire CrossBridge Bio for up to $300m
J&J reports 12-month data for Varipulse PFA platform
Vir Biotechnology doses first patient in Phase I VIR-5500 trial
MSD, Daiichi Sankyo’s ifinatamab deruxtecan receives FDA priority

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.

Contact Us